產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- 新型冠狀病毒:用于診斷的假病毒標(biāo)準(zhǔn)品和用于藥物研發(fā)的假病毒模型
- 【藥靶模型】ESR1 Y537S模型開(kāi)發(fā)
- 重磅!科學(xué)家成功利用免疫細(xì)胞運(yùn)輸抗癌藥物至腫瘤靶點(diǎn)
- 細(xì)胞株開(kāi)發(fā)的主要過(guò)程要知道
- 潛力十足的T細(xì)胞療法,我們用得起嗎?
- IL9細(xì)胞篩選模型
- 基于納米顆粒的組合免疫療法對(duì)致命性癌癥發(fā)起三重打擊
- BTK細(xì)胞篩選模型
- 能量平衡的重要靶點(diǎn)——CRF1R和CRF2R
- MTHFR基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73255CSF3R S783fs/BaF3

- 詳細(xì)內(nèi)容
CBP73255 | |
I. Introduction | |
Cell Line Name: | CSF3R S783fs/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
CSF3R S783fs results in a change in the amino acid sequence of the Csf3r protein beginning at aa 783 of 836, likely resulting in premature truncation of the functional protein (UniProt.org). S783fs does not result in increased Stat3 activation (PMID: 23656643, PMID: 24403076), however, results in increased Src activation and transformation in cell culture (PMID: 23656643), and therefore, is predicted to result in a gain of Csf3r protein function. | |
III. Representative Data | |
1.WB of CSF3R S783fs/BaF3 | |
2. Anti-proliferation assay | |
Figure 2. Anti-proliferation assay of three reference compounds on the CSF3R S783fs/BaF3. |